Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
On August 12, 2021, Zealand Pharma A/S (Nasdaq: ZEAL) announced its H1 2021 financial results, reporting revenue of DKK 132.1 million, a decrease from DKK 233.4 million in H1 2020. Net operating expenses rose to DKK 616.6 million from DKK 437.2 million. The company launched ZEGALOGUE® (dasiglucagon) in the U.S., aimed at treating severe hypoglycemia in diabetes patients. Zealand Pharma's cash reserves stood at DKK 1,282.9 million. Despite declines in revenue and increased expenses, the company is focused on expanding its pipeline with multiple clinical trials and aims to introduce five marketed products by 2025.
Zealand Pharma will host a conference call on August 12, 2021, at 4 pm CET (10 am ET) to discuss its Q2 2021 results. Presenters include CEO Emmanuel Dulac, CFO Matt Dallas, and CMO Adam Steensberg. The event will feature a Q&A session and will be conducted in English. Dial-in numbers for various regions, including the US, UK, and Denmark, are provided. A live audio webcast and slide presentation will be accessible on Zealand's investor website. Participants should register 30 minutes prior. A recording will be available post-call.
Zealand Pharma A/S has completed its share repurchase program, acquiring up to DKK 32,070,896 worth of shares, totaling 154,187 shares. The program, managed by Danske Bank A/S, was initiated on June 29, 2021, to support incentive programs. Following the transactions, Zealand holds a total of 218,410 shares as treasury shares, representing 0.5% of its total share capital of DKK 43,541,838. The average repurchase price per share was DKK 185.48, with a total value of DKK 28,597,426.
Zealand Pharma A/S announced a share repurchase program initiated on June 29, 2021, aimed at acquiring up to DKK 32,070,896 in Danish common stock for incentive programs. Danske Bank A/S manages the program independently. As of the latest transactions, Zealand has repurchased a total of 134,065 shares, valued at DKK 24,886,411. This represents 0.46% of the total share capital of Zealand, which stands at DKK 43,541,838. The program is set to conclude by July 29, 2021.
Zealand Pharma A/S announced on July 13, 2021, the continuation of its share repurchase program initiated on June 29, with a cap of DKK 32,070,896 to acquire up to 154,187 Danish common shares. The program, managed by Danske Bank A/S, is set to complete by July 29, 2021. Transactions since July 6, 2021, included the purchase of 36,000 shares at an average price of DKK 191.13, totaling DKK 6,861,210. Zealand currently holds 149,223 treasury shares, equating to 0.34% of its total share capital of DKK 43,541,838.
On June 29, 2021, Zealand Pharma A/S initiated a share repurchase program, planning to acquire up to DKK 32,070,896 worth of shares for incentive programs. Danske Bank A/S is managing the program, expected to complete by July 29, 2021, acquiring up to 154,187 shares. As of July 5, 2021, Zealand repurchased 49,000 shares at an average price of DKK 185.07, totaling DKK 9,068,340. With these transactions, Zealand holds 113,223 treasury shares, representing 0.0026% of its total share capital.
Zealand Pharma A/S announced the total number of shares and voting rights on June 30, 2021, following an increase in share capital due to employee warrants exercises. As of this date, Zealand maintains 43,541,838 shares and 43,541,838 voting rights, reflecting no changes in share capital since the previous reporting. Zealand Pharma focuses on peptide-based medicines, having two products on the market and several in clinical development. The company continues to engage in collaborations to expand the reach of its medicines.
Zealand Pharma announced it will present three posters on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA) from June 30 to July 2, 2021, in Auckland, New Zealand. The data focus on treating Short Bowel Syndrome (SBS) and suggest no need for dosage adjustments in patients with renal impairment. The company emphasizes the potential of glepaglutide as a long-acting GLP-2 analog, with significant implications for SBS management.
Zealand Pharma A/S announced a share buy-back program beginning June 29, 2021, in accordance with the Safe Harbour Regulation. The program has a maximum budget of DKK 32,070,896 and will repurchase up to 154,187 shares. Danske Bank A/S will manage the repurchases independently. The buy-back will adhere to trading limits and pricing constraints. Currently, Zealand holds 64,223 treasury shares, representing 0.01% of total share capital. The program aims to enhance employee incentive structures and is set to conclude by July 29, 2021.
Zealand Pharma has announced the U.S. commercial availability of ZEGALOGUE® (dasiglucagon) injection for treating severe hypoglycemia in patients with diabetes aged 6 and older. ZEGALOGUE is now available in both an auto-injector and prefilled syringe format. The company also introduced the ConnectedCare patient support program to provide educational and affordability resources. The FDA approved ZEGALOGUE on March 22, 2021. The treatment aims to enhance safety for patients with diabetes, addressing the critical nature of severe hypoglycemic events.